E. Jensen

1.4k total citations · 1 hit paper
19 papers, 896 citations indexed

About

E. Jensen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, E. Jensen has authored 19 papers receiving a total of 896 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in E. Jensen's work include Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (4 papers). E. Jensen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (4 papers). E. Jensen collaborates with scholars based in United States, Spain and Japan. E. Jensen's co-authors include F. Stephen Hodi, Caroline Robert, Amita Patnaik, Adil Daud, Richard Kefford, Anthony M. Joshua, Wen‐Jen Hwu, Tara C. Mitchell, Hassane M. Zarour and Omid Hamid and has published in prestigious journals such as Clinical Infectious Diseases, British Journal of Cancer and Annals of Oncology.

In The Last Decade

E. Jensen

18 papers receiving 874 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

2019 638 citations Omid Hamid, Caroline Robert et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Jensen United States	10	716	276	235	210	79	19	896
James W. Smithy United States	11	538 0.8×	265 1.0×	146 0.6×	205 1.0×	105 1.3×	41	691
Charlotte Domblides France	14	404 0.6×	205 0.7×	201 0.9×	236 1.1×	105 1.3×	45	734
Fareeda Hosein United States	4	472 0.7×	190 0.7×	119 0.5×	146 0.7×	53 0.7×	8	581
Neil M. Barth United States	20	640 0.9×	552 2.0×	227 1.0×	177 0.8×	116 1.5×	41	953
Lorenza Di Guardo Italy	15	987 1.4×	398 1.4×	360 1.5×	248 1.2×	49 0.6×	48	1.2k
Suthee Rapisuwon United States	11	683 1.0×	246 0.9×	329 1.4×	158 0.8×	104 1.3×	30	997
William Waterfield United States	7	997 1.4×	497 1.8×	245 1.0×	153 0.7×	76 1.0×	13	1.1k
Cory Batenchuk United States	10	660 0.9×	186 0.7×	135 0.6×	356 1.7×	183 2.3×	16	881
Charlotte Lemech Australia	16	389 0.5×	146 0.5×	262 1.1×	114 0.5×	81 1.0×	63	695
Vamsidhar Velcheti United States	16	1.1k 1.6×	602 2.2×	217 0.9×	443 2.1×	148 1.9×	32	1.4k

Countries citing papers authored by E. Jensen

Since Specialization

Citations

This map shows the geographic impact of E. Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Jensen more than expected).

Fields of papers citing papers by E. Jensen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Jensen. The network helps show where E. Jensen may publish in the future.

Co-authorship network of co-authors of E. Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of E. Jensen. A scholar is included among the top collaborators of E. Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Jensen. E. Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Wakelee, Heather A., Shugeng Gao, Moïshe Liberman, et al.. (2025). LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671. Annals of Oncology. 36. S1607–S1608.

Jones, David R., Moïshe Liberman, Terufumi Kato, et al.. (2024). OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 19(10). S8–S8. 5 indexed citations

Gao, Shugeng, Moïshe Liberman, Kun Chen, et al.. (2024). 1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study. Annals of Oncology. 35. S778–S779. 1 indexed citations

Gadgeel, Shirish M., Delvys Rodríguez‐Abreu, Balázs Halmos, et al.. (2023). OA14.05 5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%. Journal of Thoracic Oncology. 18(11). S77–S78. 3 indexed citations

Kowalski, Dariusz M., Alexander Luft, David Vicente Baz, et al.. (2022). 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S993–S994. 8 indexed citations

Rodríguez‐Abreu, Delvys, Martin Reck, K. Park, et al.. (2022). 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 33. S30–S31. 2 indexed citations

Colombo, Nicoletta, Domenica Lorusso, A. Casado Herráez, et al.. (2021). 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Annals of Oncology. 32. S729–S730. 18 indexed citations

Dent, Rebecca, Javier Cortés, Lajos Pusztai, et al.. (2020). 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC). Annals of Oncology. 31. S1241–S1242. 7 indexed citations

Yusof, Mastura Md, David W. Cescon, Hope S. Rugo, et al.. (2020). 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia. Annals of Oncology. 31. S1257–S1257. 3 indexed citations

10.

Brahmer, Julie R., Delvys Rodríguez‐Abreu, Rina Hui, et al.. (2020). LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%. Annals of Oncology. 31. S1181–S1182. 61 indexed citations

11.

Reck, Martin, Delvys Rodríguez‐Abreu, Rina Hui, et al.. (2019). OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S243–S243. 29 indexed citations

12.

Hamid, Omid, Caroline Robert, Adil Daud, et al.. (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology. 30(4). 582–588. 638 indexed citations breakdown →

13.

Herbst, Roy S., Edward B. Garon, D.-W. Kim, et al.. (2018). Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Annals of Oncology. 29. viii749–viii749. 17 indexed citations

14.

Herbst, Roy S., Edward B. Garon, D.-W. Kim, et al.. (2018). Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. Annals of Oncology. 29. x42–x43. 22 indexed citations

15.

Petrylak, Daniel P., Nicholas J. Vogelzang, Yves Fradet, et al.. (2017). Subgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc). Annals of Oncology. 28. v298–v298. 5 indexed citations

16.

Tomassini, Joanne E., T Mazzone, Ronald Goldberg, et al.. (2009). Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obesity and Metabolism. 11(9). 855–864. 18 indexed citations

17.

Connor, Bradley A., John Phair, David A. Sack, et al.. (2001). Randomized, Double-Blind Study in Healthy Adults to Assess the Boosting Effect of Vaqta or Havrix after a Single Dose of Havrix. Clinical Infectious Diseases. 32(3). 396–401. 15 indexed citations

18.

Clemmesen, J, Nielsen Am, & E. Jensen. (1953). Mortality and incidence of cancer of the lung in Denmark and some other countries.. PubMed. 9(3). 603–36. 20 indexed citations

19.

Clemmesen, J, Nielsen Am, & E. Jensen. (1953). The Increase in Incidence of Carcinoma of the Lung in Denmark, 1931 to 1950. British Journal of Cancer. 7(1). 1–9. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact